Current financial headlines

Sharemaestro Newsreel

Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.

Showing
1801–1836
Headlines
2156
Sources here
15
Companies here
11
Current section United States Drug Manufacturers - General news

Chronological news

Earlier headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Новости GxP Earnings Main company 🇺🇸 United States

How Dave Ricks transformed Eli Lilly – and the perils of the obesity drug boom

Under CEO Dave Ricks, Eli Lilly has undergone a significant transformation, growing its market capitalization 14-fold and becoming a global powerhouse, largely thanks to its successful obesity drugs Mounjaro and Zepbound. Ricks sped up drug development, invested heavily in manufacturing, and strategized to compete …

LLY main company
Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3% LLY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Earnings Main company 🇺🇸 United States

BofA cuts Biogen stock price target on higher expectations bar

BofA Securities has lowered its price target for Biogen Inc. (NASDAQ:BIIB) to $215 from $217, maintaining a Neutral rating, citing a higher bar for sustaining momentum after recent strong performance. Despite the cut, the stock has seen a 63% return over the past year …

BIIB main company
Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3% BIIB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Regulatory and legal Main company 🇺🇸 United States

Weight-loss wars: Why Novo Nordisk is suing Eli Lilly

Novo Nordisk (NVO) is suing Eli Lilly (LLY) for misleading advertising. Morning Brief host Julie Hyman discusses the details with Yahoo Finance Breaking Business News Reporter Jake Conley and Payne Capital Management president Ryan Payne. Video Transcript 00:00 Speaker A Novo Nordisk is filing …

NVO main company
Sharemaestro market context Trend signal started 52 weeks -16.7% NVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Fierce Pharma Market update Main company 🇺🇸 United States

Gilead, Merck’s phase 3 data back first weekly HIV pill

New phase 3 data from two Islend clinical trials indicate that the experimental once-weekly, single-tablet combination of Gilead’s lenacapavir and Merck’s islatravir (ISL/LEN) effectively maintains HIV viral suppression, matching daily treatments like Gilead’s Biktarvy. If approved, ISL/LEN would be the first complete weekly oral …

MRK main company GILD main company
Sharemaestro market context Trend signal active 52 weeks +60.7% MRK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇺🇸 United States

Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure

– Long-Term Data from the PURPOSE 1 and PURPOSE 2 Trials Demonstrate Continued High Efficacy, High Adherence and Consistent Safety Profile of Twice-Yearly Lenacapavir for PrEP – – Detailed Phase 3 Results from the ISLEND-1 and ISLEND-2 Trials Highlight the Potential of Weekly HIV …

GILD main company
Sharemaestro market context Price above Trend Line 52 weeks +23.7% GILD stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Market update Main company 🇺🇸 United States

Why Agios Pharma, A Novo Rival, Just Pulled A Bearish Move

Agios Pharmaceuticals dropped its next-generation sickle cell drug Tuesday after a failed Phase 2 study. Agios stock tumbled. Continue Reading

NVO main company
Sharemaestro market context Trend signal started 52 weeks -16.7% NVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

What to Watch in Pfizer's Non-Oncology Portfolio This Earnings Season

This article previews Pfizer's second-quarter 2026 earnings, focusing on the expected performance of its non-oncology segments. It highlights key products like Eliquis, Prevnar, Comirnaty, Paxlovid, Abrysvo, Vyndaqel, and Xeljanz, detailing projected sales trends. The piece also touches on Pfizer's competitive landscape, stock performance, and …

PFE main company
Sharemaestro market context Price above Trend Line 52 weeks +8.9% PFE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇺🇸 United States

Compared to Estimates, Novartis (NVS) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2026, Novartis (NVS) reported revenue of $14.41 billion, up 2.5% over the same period last year. EPS came in at $2.41, compared to $2.42 in the year-ago quarter. The reported revenue represents a surprise of +3.3% over the Zacks …

NVS main company
Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2% NVS stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇺🇸 United States

Novartis Q2 2026 earnings beat as cancer, MS drugs drive growth

Novartis reported second-quarter net sales of $14.4 billion on Tuesday, up 3% in dollar terms and 1% in constant currencies, as strong demand for cancer and multiple sclerosis treatments helped the Swiss drugmaker return to sales growth despite a steep drop in its top-selling …

NVS main company
Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2% NVS stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇺🇸 United States

U.S. stocks set for higher open as strong earnings boost market sentiment: Dow Jones, S&P, Nasdaq, Wall Street Futures

Wall Street bull ©Shutterstock Earnings optimism supports pre-market gains U.S. stock futures pointed to a firmer open on Tuesday as investors looked to recover from the previous session's decline, with upbeat corporate earnings encouraging buying across several sectors. Market sentiment improved after a series …

NVS main company
Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2% NVS stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Net income of Pfizer Inc. – BCS:PFECL1

The article provides a title related to the net income of Pfizer Inc. with the stock symbol BCS:PFECL1. It indicates that the market for this particular stock on the Santiago Stock Exchange was closed with no trades. The content is mostly boilerplate from TradingView, …

PFE main company
Sharemaestro market context Price above Trend Line 52 weeks +8.9% PFE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Moomoo Deals and strategy Main company 🇺🇸 United States

Press Release: Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio

Gilead Sciences has announced the completion of its strategic acquisition of Tubulis, a German-based biotechnology company. This acquisition is set to enhance Gilead's oncology portfolio, particularly in the area of antibody-drug conjugates (ADCs) for cancer treatment. The integration of Tubulis's innovative ADC platform and …

GILD main company
Sharemaestro market context Price above Trend Line 52 weeks +23.7% GILD stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇺🇸 United States

Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this drugmaker have …

NVO main company
Sharemaestro market context Trend signal started 52 weeks -16.7% NVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Market update Main company 🇺🇸 United States

Pharma heavyweights clash over anti-obesity drug ads

Anti-obesity treatments have been a financial windfall for Novo Nordisk and Eli Lily (SEBASTIEN BOZON) Danish pharmaceuticals heavyweight Novo Nordisk said Tuesday it is suing its arch US rival, Eli Lilly, over "false and materially misleading" adverts for their competing weight-loss and anti-diabetes treatments. …

NVO main company
Sharemaestro market context Trend signal started 52 weeks -16.7% NVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇺🇸 United States

Gilead Sciences' Quarterly Earnings Preview: What You Need to Know

Gilead sign is seen during the fifth China International Import Expo By Eagle Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need. Valued at $166.7 billion by …

GILD main company
Sharemaestro market context Price above Trend Line 52 weeks +23.7% GILD stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇺🇸 United States

Novartis Bounds For Buy Point. Why Shares Are On The Rise.

Novartis stock jumped early Tuesday on better-than-expected second-quarter metrics, partially driven by Cosentyx. Continue Reading

NVS main company
Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2% NVS stored weekly price path from 22 Aug 2025 to 14 Aug 2026
www.marketscreener.com Earnings Main company 🇺🇸 United States

BofA Securities Adjusts Biogen Price Target to $215 From $217

BofA Securities has lowered its price target for Biogen (NASDAQ: BIIB) shares to $215 from $217. This adjustment follows other recent analyst updates, including Guggenheim maintaining a Buy rating with a $280 target and Goldman Sachs maintaining a Buy rating with a $271 target. …

BIIB main company
Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3% BIIB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Regulatory and legal Main company 🇺🇸 United States

Novo Nordisk sues Eli Lilly in high-stakes GLP-1 advertising feud

Investing.com -- The clash between pharma titans Novo Nordisk and Eli Lilly just escalated from the pharmacy counter to the courtroom. Novo Nordisk Inc. filed a lawsuit in the U.S. District Court for the District of New Jersey against Eli Lilly and Company and …

NVO main company
Sharemaestro market context Trend signal started 52 weeks -16.7% NVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
GlobeNewswire Market update Main company 🇺🇸 United States

Press Release: Sanofi evolves its Executive Committee to support its next strategic chapter

Sanofi has announced significant changes to its Executive Committee, effective September 1, 2026, to streamline leadership across its businesses, R&D, and global functions. These changes are intended to support the company's strategic priorities and prepare for its next growth chapter. Key appointments include new …

SNY main company
Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1% SNY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Reuters Regulatory and legal Main company 🇺🇸 United States

Novo Nordisk says it is suing Eli Lilly, accusing it of false advertising

Novo Nordisk has filed a lawsuit against Eli Lilly, accusing its rival of false advertising regarding its weight-loss medications. Novo Nordisk alleges that Eli Lilly's advertising campaigns for Zepbound and Mounjaro misleadingly compare the highest approved doses of Lilly's drugs with lower, outdated doses …

LLY main company
Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3% LLY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Regulatory and legal Main company 🇺🇸 United States

Novo Nordisk Sues Eli Lilly Over Zepbound and Mounjaro Ads

(Bloomberg) -- Novo Nordisk A/S is suing Eli Lilly & Co. in US federal court, claiming that Lilly's advertising for its blockbuster obesity shot Zepbound and diabetes injection Mounjaro is misleading as competition between the two drugmakers escalates. Most Read from Bloomberg Yemen's Houthis …

LLY main company
Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3% LLY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Ad-hoc-news.de Deals and strategy Main company 🇺🇸 United States

Merck stock trades steadily as Keytruda and vaccine revenue underpin earnings

Merck & Co. continues to demonstrate steady growth, primarily driven by strong revenue from its cancer drug Keytruda and its vaccines portfolio. Despite looming patent expiries, the company's fiscal 2024 and early 2025 reports show double-digit revenue increases in oncology and vaccines, alongside improved …

MRK main company
Sharemaestro market context Trend signal active 52 weeks +60.7% MRK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TIKR.com Deals and strategy Main company 🇺🇸 United States

Eli Lilly Just Bought a Psychedelics Company for $3.8 Billion. Washington Is Watching the Buying Spree

Eli Lilly recently acquired AtaiBeckley, a psychedelics company, for up to $3.8 billion, marking its eleventh drugmaker acquisition of 2026. While the deal itself is a small fraction of Lilly's revenue and cash flow, which is greatly boosted by its obesity drugs, the rapid …

LLY main company
Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3% LLY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇺🇸 United States

Novartis Q2 profits recover as revenue mantle passes to newer medicines

Despite a lacklustre start to the year, Novartis seems to have overcome its financial slump, reporting operating profits in Q2 that exceeded analyst expectations. The Swiss drugmaker's core operating income for the quarter was $5.94bn, representing flat year-over-year growth. However, this was ahead of …

NVS main company
Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2% NVS stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Reuters Earnings Main company 🇺🇸 United States

Novartis CEO Vas Narasimhan says 'no change of plans'

Novartis CEO Vas Narasimhan confirmed his commitment to leading the company through its next phase of growth, despite a period of significant patent expiries. He expressed anticipation for upcoming drug trial data announcements and new product launches, highlighting a focus on AI transformation. Narasimhan …

NVS main company
Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2% NVS stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Deals and strategy Main company 🇺🇸 United States

Novartis returns to sales growth in Q2 as newer medicines offset generic pressure (NVS)

Researcher with pipette ©National Institutes of Health New therapies drive quarterly revenue increase Novartis AG (NYSE:NVS) reported higher second-quarter sales on Tuesday, with strong demand for its newer medicines helping to offset the continued impact of generic competition and supporting the company's decision to …

NVS main company
Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2% NVS stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TipRanks Capital return Main company 🇺🇸 United States

Novo Nordisk Ramps Up DKK 15 Billion Share Buyback Programme

Novo Nordisk has initiated a share repurchase program targeting up to DKK 15 billion in buybacks over 12 months, starting February 4, 2026. The company had repurchased nearly 25 million B shares by July 17, 2026, holding 0.9% of its share capital as treasury …

NVO main company
Sharemaestro market context Trend signal started 52 weeks -16.7% NVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Market source Earnings Main company 🇺🇸 United States

The Zacks Analyst Blog Highlights Johnson & Johnson, Lam Research, Seagate, KVH Industries and Dawson Geophysical

The Zacks Analyst Blog features research reports on 16 major stocks, including Johnson & Johnson, Lam Research Corp., and Seagate Technology Holdings plc, along with micro-caps KVH Industries, Inc. and Dawson Geophysical Co. The reports highlight company performance, growth drivers, and potential headwinds, with …

JNJ main company
Sharemaestro market context Trend signal active 52 weeks +48.8% JNJ stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Morningstar Macro sensitivity Main company 🇺🇸 United States

Phanes Therapeutics Announces Expansion of Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate Spevatamig in Combination with KEYTRUDA® (Pembrolizumab) and Chemotherapy for Treatment of Biliary Tract Cancer

Phanes Therapeutics has expanded its clinical trial collaboration with Merck to include the evaluation of spevatamig, Phanes' anti-CLDN18.2/CD47 bispecific antibody, in combination with KEYTRUDA® and chemotherapy. This expanded agreement focuses on the first-line treatment of biliary tract cancer (BTC), acknowledging the high unmet medical …

MRK main company
Sharemaestro market context Trend signal active 52 weeks +60.7% MRK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Hollencrest Capital Management Purchases 8,921 Shares of Johnson & Johnson $JNJ

Hollencrest Capital Management significantly increased its stake in Johnson & Johnson (NYSE:JNJ) by 142% in the first quarter, acquiring an additional 8,921 shares to bring its total holdings to 15,204 shares valued at $3.7 million. This move coincides with increasing analyst optimism for JNJ, …

JNJ main company
Sharemaestro market context Trend signal active 52 weeks +48.8% JNJ stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Meeder Advisory Services Inc. Acquires 4,916 Shares of Johnson & Johnson $JNJ

Meeder Advisory Services Inc. increased its stake in Johnson & Johnson by 8.3% in the first quarter, purchasing an additional 4,916 shares. This acquisition brings their total holdings to 63,813 shares, valued at $15.598 million, making J&J their 27th largest position. The article also …

JNJ main company
Sharemaestro market context Trend signal active 52 weeks +48.8% JNJ stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Johnson & Johnson $JNJ Shares Sold by KBC Group NV

KBC Group NV significantly reduced its stake in Johnson & Johnson (JNJ) by selling over 1 million shares in the first quarter, though it still holds a substantial position. Despite this sale, Wall Street analysts maintain a "Moderate Buy" rating for JNJ with an …

JNJ main company
Sharemaestro market context Trend signal active 52 weeks +48.8% JNJ stored weekly price path from 22 Aug 2025 to 14 Aug 2026
www.marketscreener.com Analyst action Main company 🇺🇸 United States

ASTRAZENECA : JP Morgan gives a Buy rating

JP Morgan analyst Richard Vosser has reaffirmed a "Buy" rating for AstraZeneca PLC, keeping the target price unchanged at GBX 12380. The pharmaceutical company's stock shows a 0.90% increase, with recent news including Novartis's strong profit and various updates in the biotech sector. AstraZeneca's …

AZN main company
Sharemaestro market context Price below Trend Line 52 weeks -1.4% AZN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Commerzbank Aktiengesellschaft FI Raises Position in Amgen Inc. $AMGN

Commerzbank Aktiengesellschaft FI significantly increased its stake in Amgen Inc. by 31.1% in the first quarter, now holding 194,785 shares valued at $68.535 million. This makes Amgen its 23rd largest holding. Other institutional investors also adjusted their positions in Amgen, while one insider, SVP …

AMGN main company
Sharemaestro market context Trend signal active 52 weeks +44.4% AMGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Andra AP fonden Has $17.72 Million Stock Position in Amgen Inc. $AMGN

Andra AP fonden reduced its stake in Amgen Inc. by 18.9% in the first quarter, now holding 50,366 shares valued at $17.72 million. Other institutional investors also adjusted their positions, and 76.50% of Amgen's stock is institutionally owned. Amgen's stock opened at $364.17, and …

AMGN main company
Sharemaestro market context Trend signal active 52 weeks +44.4% AMGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Ad-hoc-news.de Earnings Main company 🇺🇸 United States

Merck stock trades steady as oncology and vaccines drive revenue growth

Merck's stock is trading steadily due to strong revenue growth from its oncology and vaccine segments, particularly from Keytruda and Gardasil. The company is heavily investing in research and development to maintain its long-term growth and diversify its portfolio, while also navigating a competitive …

MRK main company
Sharemaestro market context Trend signal active 52 weeks +60.7% MRK stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context